Literature DB >> 33929846

Monoubiquitination of KRAS at Lysine104 and Lysine147 Modulates Its Dynamics and Interaction with Partner Proteins.

Vinay V Nair1,2, Guowei Yin3,4, Jerry Zhang3, John F Hancock1,2, Sharon L Campbell3,5, Alemayehu A Gorfe1,2.   

Abstract

KRAS, a 21 kDa guanine nucleotide-binding protein that functions as a molecular switch, plays a key role in regulating cellular growth. Dysregulation of this key signaling node leads to uncontrolled cell growth, a hallmark of cancer cells. KRAS undergoes post-translational modification by monoubiquitination at various locations, including at lysine104 (K104) and lysine147 (K147). Previous studies have suggested that K104 stabilizes helix-2/helix-3 interactions and K147 is involved in nucleotide binding. However, the impact of monoubiquitination at these residues on the overall structure, dynamics, or function of KRAS is not fully understood. In this study, we examined KRAS monoubiquitination at these sites using data from extensive (12 μs aggregate time) molecular dynamics simulations complemented by nuclear magnetic resonance spectroscopy data. We found that ubiquitin forms dynamic nonspecific interactions with various regions of KRAS and that ubiquitination at both sites modulates conformational fluctuations. In both cases, ubiquitin samples a broad range of conformational space and does not form long-lasting noncovalent contacts with KRAS but it adopts several preferred orientations relative to KRAS. To examine the functional impact of these preferred orientations, we performed a systematic comparison of the dominant configurations of the ubiquitin/KRAS simulated complex with experimental structures of KRAS bound to regulatory and effector proteins as well as a model membrane. Results from these analyses suggest that conformational selection and population shift may minimize the deleterious effects of KRAS ubiquitination at K104 and K147 on binding to some but not all interaction partners. Our findings thus provide new insights into the steric effects of ubiquitin and suggest a potential avenue for therapeutic targeting.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33929846      PMCID: PMC8664378          DOI: 10.1021/acs.jpcb.1c01062

Source DB:  PubMed          Journal:  J Phys Chem B        ISSN: 1520-5207            Impact factor:   2.991


  50 in total

1.  The small GTPases K-Ras, N-Ras, and H-Ras have distinct biochemical properties determined by allosteric effects.

Authors:  Christian W Johnson; Derion Reid; Jillian A Parker; Shores Salter; Ryan Knihtila; Petr Kuzmic; Carla Mattos
Journal:  J Biol Chem       Date:  2017-06-19       Impact factor: 5.157

2.  VMD: visual molecular dynamics.

Authors:  W Humphrey; A Dalke; K Schulten
Journal:  J Mol Graph       Date:  1996-02

3.  CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data.

Authors:  Jing Huang; Alexander D MacKerell
Journal:  J Comput Chem       Date:  2013-07-06       Impact factor: 3.376

Review 4.  KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.

Authors:  Andrew M Waters; Channing J Der
Journal:  Cold Spring Harb Perspect Med       Date:  2018-09-04       Impact factor: 6.915

5.  PIP2 Influences the Conformational Dynamics of Membrane-Bound KRAS4b.

Authors:  Mark A McLean; Andrew G Stephen; Stephen G Sligar
Journal:  Biochemistry       Date:  2019-08-01       Impact factor: 3.162

6.  Ras membrane orientation and nanodomain localization generate isoform diversity.

Authors:  Daniel Abankwa; Alemayehu A Gorfe; Kerry Inder; John F Hancock
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

7.  Oncogenic K-Ras Binds to an Anionic Membrane in Two Distinct Orientations: A Molecular Dynamics Analysis.

Authors:  Priyanka Prakash; Yong Zhou; Hong Liang; John F Hancock; Alemayehu A Gorfe
Journal:  Biophys J       Date:  2016-03-08       Impact factor: 4.033

Review 8.  Dragging ras back in the ring.

Authors:  Andrew G Stephen; Dominic Esposito; Rachel K Bagni; Frank McCormick
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

9.  Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition.

Authors:  Jenny Y Xue; Yulei Zhao; Jordan Aronowitz; Trang T Mai; Alberto Vides; Besnik Qeriqi; Dongsung Kim; Chuanchuan Li; Elisa de Stanchina; Linas Mazutis; Davide Risso; Piro Lito
Journal:  Nature       Date:  2020-01-08       Impact factor: 49.962

10.  Approaches to inhibiting oncogenic K-Ras.

Authors:  Alemayehu A Gorfe; Kwang-Jin Cho
Journal:  Small GTPases       Date:  2019-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.